Results 211 to 220 of about 2,815,823 (291)

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Combined red blood cell distribution width and neutrophil-to-lymphocyte ratio and risk of composite cardiovascular events in patients with moderate-to-severe obstructive sleep apnea: a prospective cohort study. [PDF]

Front Med (Lausanne)
Li N, Liu H, Zhang L, Chang M, Xia Y.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Integration of proxy intermediate omics traits into a nonlinear two-step model for accurate phenotypic prediction. [PDF]

Theor Appl Genet
Yoshioka H, Mary-Huard T, Aubert J, Toda Y, Ohmori Y, Yamasaki Y, Tsujimoto H, Takahashi H, Nakazono M, Takanashi H, Fujiwara T, Tsuda M, Kaga A, Inaba J, Fuji Y, Hirai MY, Nose Y, Kumaishi K, Usui E, Kobori S, Sato T, Narukawa M, Ichihashi Y, Iwata H.   +23 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Transient miR-92a Induction in Intermediate Monocytes (CD14⁺⁺CD16⁺) in Acute Coronary Syndrome (ACS). [PDF]

Int J Mol Sci
Harbaum L, Kreutz J, Weibler C, Euler G, Malysa M, Raifer H, Schieffer B, Grote K, Parahuleva M.   +8 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. [PDF]

Ann Hematol
Leung GMK, Ye Y, Luo Y, Shi J, Zhao Y, Sim JPY, Kwong YL, He H, Gill H.   +8 more
europepmc   +1 more source